<DOC>
	<DOC>NCT01076361</DOC>
	<brief_summary>The Medtronic CapSure Epi Lead Post-approval Study will assess long-term safety of the 4968 lead. This study is part of the Medtronic System Longevity Study.</brief_summary>
	<brief_title>Model 4968 CAPTURE EPIÂ® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study</brief_title>
	<detailed_description>The Medtronic CapSure Epi Lead Post-approval Study is being conducted as part of the requirements to satisfy the PMA conditions of approval for the Model 4968 lead. 100 subjects (adult and pediatric) with a 4968 lead will be followed for a minimum of five years to assess the long-term safety of the leads.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Provision of written informed consent and/or authorization for access to and use of health information by subjects or appropriate legal guardians as required by an institution's Investigational Review Board, Medical Ethics Board, or Research Ethics Board Availability of implant, followup, and productrelated event data Implanted with a Model 4968 Capsure Epi Lead Subjects receiving an implant of a Medtronic lead at a nonparticipating center and the implant data and current status cannot be confirmed within 30 days after implant Subjects who are, or will be inaccessible for followup at a 4968 Postapproval study center Subjects implanted with a Medtronic cardiac therapy device whose predetermined enrollment limit for that specific product has been exceeded Subjects with exclusion criteria required by local law</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Epicardial</keyword>
	<keyword>Pacing Lead</keyword>
</DOC>